Treatment Considerations and Safety Updates in Metastatic Pancreatic Adenocarcinoma
March 10, 2026
Key Points
-
Metastatic pancreatic adenocarcinoma remains a poor-prognosis disease, though multiple systemic therapy options are available depending on patient fitness and treatment tolerance.
-
Modified FOLFIRINOX or 5-FU plus nanoliposomal irinotecan are commonly used for patients who can tolerate intensive therapy, while gemcitabine-based regimens are often considered for older or frail individuals.
-
The FDA now recommends DPYD testing, as patients with DPYD mutations may face a higher risk of severe fluoropyrimidine-related toxicity.
Treatment Selection and DPYD Testing Considerations
During a recent discussion, Rohit Gosain, MD, of Roswell Park Comprehensive Cancer Center, and Rahul Gosain, MD, MBA, of Wilmot Cancer Institute, reviewed current treatment considerations for metastatic pancreatic adenocarcinoma, which continues to carry a poor prognosis. Common systemic therapy regimens include modified FOLFIRINOX or 5-fluorouracil (5-FU) plus nanoliposomal irinotecan for patients who can tolerate more intensive therapy. For older or frail patients, less intensive approaches, such as gemcitabine plus nab-paclitaxel or single-agent gemcitabine, are often considered.
Dr. Rahul Gosain also highlighted an important safety update related to fluoropyrimidine therapy. The FDA label for 5-FU now recommends dihydropyrimidine dehydrogenase (DPYD) testing, as patients with DPYD mutations may be at increased risk for severe toxicity when treated with fluoropyrimidines.